Explicit Sensory Retraining for Chemo-Induced Peripheral Neuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cross-over randomized trial evaluates the effect of explicit sensory retraining for the lower extremities in adults with chemotherapy-induced peripheral neuropathy. Participants receive three sessions, each spaced about a week apart, and outcomes include subjective symptom scores, pain, mobility, balance, sensory thresholds, and proprioception. The study uses measures such as TNAS, VAS, TUG, FABS, monofilament touch testing, and a home exercise log. CIPN is a common, long-lasting complication of chemotherapy that can impair function and quality of life, especially in sensory fibers of the feet and legs. Active sensory rehabilitation has shown benefit in other neurological conditions, and this trial investigates its applicability to CIPN.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* CIPN by self-report (present or absent) \> 3 months after last chemotherapy treatment
* age \> 18.

Exclusion Criteria:

* Pre-chemotherapy neuropathy/ sensory impairment
* recurrent falls prior to chemotherapy (more than 2 per year)
* CNS involvement
* not ambulatory before chemotherapy
* Hebrew proficiency not meeting questionnaires' needs.

Where it's running

• Shamir Medical center
  Tzrifin, Israel Recruiting

Study contacts

• Study coordinator: Hadas Ofek, PT, PhD
• Email: hadasbarkolofek@gmail.com
• Phone: +972544666412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cryotherapy during weekly paclitaxel to reduce chemotherapy-induced numbness and tingling

  This study tests whether applying cryotherapy to hands and feet during weekly paclitaxel helps prevent CIPN in women with breast cancer.

  Recruiting at 3 sites Azienda Sanitaria dell'Alto Adige · Bolzano, Bolzano and 3 other locations · NCT07780955

• Scrambler Therapy for chemotherapy-related nerve pain (CIPN).

  Researchers will try Scrambler Therapy, a non-drug electrical treatment, to reduce pain and numbness in people with long-lasting chemotherapy-induced peripheral neuropathy.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07219472

• VMD-3866 topical gel for chemotherapy-induced nerve pain

  This trial will test whether a non-opioid topical gel called VMD-3866 can reduce pain in adults with chemotherapy-induced peripheral neuropathy.

  Recruiting Phase 2 VM Therapeutics LLC · London, UK · NCT07072468

• Cryocompression to prevent taxane-induced nerve damage in the arms and legs.

  This study tests whether cooling and pressure applied to the arms and legs during taxane chemotherapy can prevent or reduce numbness, pain, or weakness from peripheral neuropathy in adults with breast or gynecologic cancer.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07064798

• SIR2501 plus Paclitaxel for solid tumors

  This Phase 2 study tests SIR2501 in adults with solid tumors who are starting paclitaxel chemotherapy to see if it is safe and tolerable and to explore its effect on chemotherapy-induced neuropathy.

  Recruiting at 3 sites Phase 2 Sironax USA, Inc. · Hollywood, Florida and 4 other locations · NCT07765446

• Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors

  This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07673614

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.